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Introduction 
From 13 July onwards, the Interministerial Influenza Coordination Committee announced the 
switch from the containment phase to a mitigation phase due to the increased number of 
Influenza A(H1N1)2009 cases (1,2). This modified approach means that it is no longer nec-
essary to conduct a virological examination for every suspicious case and that the diagnosis 
relied on clinical criteria again. It also required the initiation of several surveillance systems 
allowing the follow-up of the infection.  
However, for some patients a virological confirmation was still needed due to their clinical 
evolution or clinical history. Because of the high amount of these requests, it was proposed 
to decentralise the diagnostic capacity from the Belgian National Influenza Centre (NIC) to a 
network of ‘partner’ laboratories.  
Therefore, all sentinel laboratories were invited to implement the diagnostic tests, to partici-
pate in epidemiological surveillance in the frame of the sentinel laboratory network, to 
participate in virological surveillance by sending laboratory results or strains to be further 
subtyped at the NIC.  
A network of 15 laboratories that responded favourably was thus installed and used as an 
additional tool for the virological surveillance of the Influenza A(H1N1)2009, allowing the 
identification of circulating types and subtypes. 
Here we report on the data gathered by this network for the period from week 40 to week 53 
of 2009. 
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Methods 
A list with all participating laboratories (n=15) was published on the internet (http://www.wiv-
isp.be/flu-surveillance/) making it available to all requestors. The analysis request form and 
instructions including the sample collection and transport conditions, the inclusion criteria, as 
well as the turnaround time for analysis were generated for each laboratory in both Dutch 
and French and published on the website. 
Based on the inclusion criteria described in the instruction document, testing focussed on 
hospitalised patients and patients at risk for severe disease for whom the results of the test 
could influence decisions regarding care and treatment. 
To support these laboratories, the analysis procedure and positive controls from positive 
samples were offered by the NIC. However, no restriction was given on the procedure, nei-
ther on the algorithm used. 
During the study period, following data were collected: sample identifiers, patient birth date, 
gender and residence, and results of the antigen detection and PCR (typing A/B and subtyp-
ing A(H1N1)2009) if available. Results were extracted weekly from the LIMS and collected by 
WIV-ISP for further data analysis.  
Results 
From 28 September 2009 (week 40) until 3 January 2010 (week 53), a total of 5942 samples 
were collected by 12 out of the 15 laboratories voluntarily participating in the network and 
providing their data. Different PCR procedures as well as confirmation algorithms were used 
by these laboratories. Four laboratories performed a screening test (antigen detection and/or 
Influenza A PCR) before subtyping for Influenza A(H1N1)2009 by PCR, 2 laboratories imme-
diately performed A(H1N1)2009 subtyping, 5 laboratories performed the typing for Influenza 
A and the subtyping for A(H1N1) 2009 simultaneously, while 1 changed its algorithm during 
the study period. 
A median of 308 samples was determined by the 12 participating laboratories, range 41-
1596 (IQR 181-532). Two laboratories, one from the Flemish region and one from the Brus-
sels-Capital Region, received together 3190 out of the 5942 samples (53.7%). 
Since the majority of the laboratories reporting the postal code were localised in the Flemish 
Region (n=6) and in Brussels (n=2), samples were mainly collected from patients from these 
regions: 3159 from Flemish region, 1403 from Brussels, 898 from the Walloon region and 
482 patients with unknown residence.  
Two out of the 7 laboratories performing the Influenza B typing detected Influenza B in 8 
samples. As no Influenza A subtyping for seasonal H1N1 and H3N2 was performed, no in-
formation could be analysed on this matter.  
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For 3139 out of the 5942 samples, an Influenza A(H1N1)2009 PCR was performed accord-
ing to their confirmation algorithm. Of these, 1464 (46.7%) samples were positive, 1649 
(52.5%) negative and 26 (0.8%) indeterminate, the latter mainly due to inhibition. All further 
data analysis is performed on these 3139 samples. 
No difference in sex ratio (M/F: 1.08) appeared with 1583 confirmed diagnoses among males 
and 1459 among females.  
As demonstrated in figure 1 the study period included the epidemic. The peak of the epi-
demic was observed in week 43 when 341 cases were detected (positivity rate 65.8%). 
Although a higher amount of samples were analysed in week 44 (n=545) as compared to 
week 43 (n=518), a smaller proportion of samples were found positive. 
The median age of the Influenza A(H1N1)2009 positive cases was 9.8 years (IQR: 3.1-25.9). 
Nearly sixty-two percent (62%) of the positive cases were found within the age group of 0-15 
years and 88% of the confirmed cases were younger than 45 years (data not shown). Based 
on the proportion of incidence by age group, a similar age distribution profile was observed 
for all participating laboratories (Figure 2). Depending on the laboratory, 75 to 99% of the 
confirmed cases were younger than 45 years, and 95% to 100% was younger than 65 years.  
The positivity rates (number of positive results on total number of samples tested) were ho-
mogeneously distributed between 30.4 and 32.9 for all but one laboratory (n=4) performing 
the Influenza A and A(H1N1)2009 PCR in one run. The other laboratory reported only posi-
tive cases and therefore a positive rate could not be calculated. For the only laboratory 
changing from algorithm strategy during the study period, a higher positivity rate of 40.9 was 
notified. 
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Figure 2: proportion of incidences by age group as analysed by the participating laboratories for Influenza 
A(H1N1)2009 cases between week 40 and 53, 2009 
Discussion 
The transfer of the Influenza virus testing to partner laboratories was promoted to increase 
the diagnostic capacity required to meet the increased demands. This allowed the NIC to 
focus its activity again on the population based surveillance, the antigenic and genetic char-
acterisation of the strains and the anti-viral resistance monitoring. 
Although the decentralisation of the activities to the participating laboratories improves the 
analysis turnaround time and thus the patient care, it reduces the completeness of the cohort 
database. The missing information for gender, residence and date of birth can be explained 
by the priorities defined by the individual laboratories. Therefore the decentralisation reduced 
the capacity and the power of the epidemiological surveillance and this information can only 
be provided by community-based surveillance programmes such as the SGP network (3,4).  
Patients included in this study were not equally distributed throughout the different regions in 
Belgium. Since one Walloon laboratory did not report the residence of its patients, the repre-
sentation of the patients group from the Walloon Region is slightly underestimated. However, 
the heterogeneous distribution should still be taken into consideration in the generalisation of 
the results to the diagnosed patients in Belgium. 
The distribution curve of the number of infected cases as a function of time had the same 
shape as the one observed by other implemented surveillance systems such as the surveil-
lance SGP network (3,4) and the paediatric surveillance (5). The peak of the number of 
positive cases was observed in week 43, after which, in week 44, the decline of the number 
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There is some evidence that the start of school holidays reduces the influenza transmission 
and that the return to school slightly accelerates the epidemic. As the decline in prevalence 
occurred before the autumn holidays (week 45) we could not confirm this hypothesis.  
The similarity in the age distribution of patients at the different laboratories demonstrates the 
age-independent inclusion criteria for these laboratories (Figure 2). 
The vulnerability for Influenza A(H1N1)2009 of the younger age groups as shown in this re-
port, was also observed by the national surveillance SGP network (3) and is consistent with 
other investigations (6,7). The very low presence of people over 65 years of age is consistent 
with other investigations (Health Protection Agency, Centers for Disease Control and Preven-
tion). Data suggest that the elderly may to some extent be protected from infection (8,9,10). 
As in many other countries, the Influenza A(H1N1)2009 virus was the predominant circulat-
ing influenza virus (6,7,11). However 8 Influenza B strains were detected by 2 out of 7 
laboratories performing this typing assay. Although these 2 laboratories reported the majority 
of samples (53.7%), this prevalence of subtype B could still be an underestimation. This is of 
notice as no Influenza B strain was detected from the samples provided by the SGP network 
(4). Whether this difference was due to the selection of patient samples or to the sensitivity or 
specificity of the assays should still be investigated. 
These data are an additional tool for the virological surveillance of Influenza A(H1N1)2009 
during the epidemic in Belgium. While the epidemiological surveillance by the SGP network 
selects patients with influenza-like illness (ILI) attending the general practitioner’s, this sur-
veillance study is focussed on hospitalised patients and patients at risk of severe diseases. 
Therefore, the obtained laboratory results provide information on the identification of the in-
fection waves during an epidemic and can be implemented as a confirmation tool of the 
population-based surveillance. 
To avoid inappropriate assignment of morbidity to the Influenza A(H1N1)2009 virus, some 
efforts to detect other respiratory viral agents are warranted. Therefore, it would be of par-
ticular interest if this virological surveillance could be enlarged with the monitoring of co-
circulating viral agents associated with ILI during the Influenza season. Similarly the link be-
tween the cases and the clinical data is lacking in this study and should be considered in a 
future study.  
Quality assessments have proven their usefulness to demonstrate similar performances be-
tween the different laboratories (12,13). Considering the heterogeneous PCR procedures 
used by the different laboratories, the organisation of such a quality assessment will be of 
upmost importance to compare the relatedness of the performances between the laborato-
ries. Meanwhile such a quality assessment was organised after the epidemic period by the 
MolecularDiagnostics.be workgroup for their members including most of the participating 
laboratories from our study. Results are available for these members through their website 
(14).  
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This study demonstrated the fluent decentralisation of the confirmatory analysis from the NIC 
towards the participating laboratories. The network and websites were successfully organ-
ised and implemented allowing the collection of virological data. This network allowed the 
reduction of the workload at the NIC as well and made the diagnosis more widely available. 
Despite the differences in testing algorithm and inclusion criteria, similar positivity rates as 
well as age distributions of the confirmed cases were notified between the laboratories. 
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